September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Retinal Embolic events following Transcatheter Aortic Valve Implantation (TAVI) for Aortic Stenosis.
Author Affiliations & Notes
  • Nirodhini Narendran
    Wolverhampton and Midland Counties Eye Infirmary, New Cross Hospital, Wolverhampton, West Midlands, United Kingdom
  • William Fusi-Rubiano
    Wolverhampton and Midland Counties Eye Infirmary, New Cross Hospital, Wolverhampton, West Midlands, United Kingdom
  • Andrew Smallwood
    Department of Cardiology, New Cross Hospital, Wolverhampton, United Kingdom
  • Randhir Chavan
    Birmingham and Midland Eye Centre, Sandwell and West Birmingham NHS Trust, Birmingham, United Kingdom
  • Yit C. Yang
    Wolverhampton and Midland Counties Eye Infirmary, New Cross Hospital, Wolverhampton, West Midlands, United Kingdom
    Birmingham and Midland Eye Centre, Sandwell and West Birmingham NHS Trust, Birmingham, United Kingdom
  • Saib Khogali
    Department of Cardiology, New Cross Hospital, Wolverhampton, United Kingdom
  • James Cotton
    Department of Cardiology, New Cross Hospital, Wolverhampton, United Kingdom
  • Footnotes
    Commercial Relationships   Nirodhini Narendran, None; William Fusi-Rubiano , None; Andrew Smallwood, None; Randhir Chavan , None; Yit Yang, None; Saib Khogali , None; James Cotton, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 91. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Nirodhini Narendran, William Fusi-Rubiano, Andrew Smallwood, Randhir Chavan, Yit C. Yang, Saib Khogali, James Cotton; Retinal Embolic events following Transcatheter Aortic Valve Implantation (TAVI) for Aortic Stenosis.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):91.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : TAVI is an established treatment for patients with severe symptomatic aortic stenosis but is complicated by subclinical cerebral emboli, in >75% of patients. This study aimed to investigate for the first time, the occurrence of retinal embolic events following TAVI.

Methods : Following informed consent, patients were screened prior to TAVI to exclude those with: history of previous retinal occlusion; ocular conditions making detection of retinal emboli difficult; contraindication to dilated pupil examination and retinal photography, any condition making transfer to ophthalmic department unsafe prior to and after TAVI and history of diabetes. Preoperatively, patients had full ophthalmic examination including confrontational field testing, fundus examination and retinal photography. Post-operatively, patients underwent bedside ophthalmic examination with confrontational field testing and dilated direct and indirect ophthalmoscopy on day 2 and final, full ophthalmic examination on day 30. New retinal microvascular abnormalities and emboli were documented with retinal photography.

Results : 20 patients were enrolled over 24 months, mean age 82 years (68-93). Technical and clinical success of the procedure was evident in all patients, with no in-hospital mortality. All patients underwent ophthalmic examination preoperatively and at 48 hours, 19 patients underwent follow up exam at 30 days. One patient had evidence of retinal embolus pre TAVI which was still evident on day 2. Two patients had new unilateral retinal emboli and one patient had unilateral splinter haemorrhage on day 30. Another patient developed a clinical stroke, but had no evidence of retinal embolus at any timepoint. No patients suffered a significant change in visual acuity or intra ocular pressure.

Conclusions : New retinal events were identified post TAVI in 15% of patients (n=3). All events occurred between 48 hours and 30 days, suggesting that they were not acute procedural emboli, the source could be the aorta or the valve itself. There may be a need to reduce the risk of embolic events by optimizing anti thrombus therapy cover during the peri-operative period.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×